Welcome to the Till Lab

The Till lab team has been conducting translational research on chimeric antigen receptor (CAR) T cells since 2006, during which time Dr. Till served as the Principal Investigator of two important gene therapy clinical trials, including the first published trial testing CAR T cells in human lymphomas, as well as the first-in-human trial testing “3rd-generation” CARs containing CD28 and 41BB costimulatory domains. The Till translational research lab has extensive experience assessing the function of CAR T cells targeting CD20 and CD19 in vitro and in mouse models, including correlative assays investigating the development of endogenous anti-tumor immune responses following CAR T cell therapy.

Dr. Till's research experience led to an invitation to chair an ASH session on novel lymphoma therapies in 2011 and 2013, participate in NIH immunotherapy workshops with national leaders in CAR T cell therapy, serve as the SWOG study coordinator of an intergroup clinical trial for mantle cell lymphoma, and serve on the editorial board of the Journal of Clinical Oncology.